Pint Pharma and Dyax Corp. Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America
Dyax Corp. a developer of novel biotherapeutics for unmet medical needs, and Pint Pharma (Pint) announced today a strategic partnership for the development and commercialization of KALBITOR® (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. KALBITOR® is marketed in United States for the treatment of acute attacks of HAE in patients 16 years of age and older.
Under the terms of the exclusive license agreement, Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Pint is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of KALBITOR® in the covered territories. Additionally, Pint will purchase drug product from Dyax on a cost-plus basis for commercial supply.
“We are pleased to announce a new partnership for KALBITOR® in Latin America, and look forward to working with Pint toward its commercialization in this region," said Gustav Christensen, President and Chief Executive Officer of Dyax Corp. “Pint’s experience in bringing novel biotherapeutics to market will be important in delivering KALBITOR® to HAE patients in this region. We continue to make strides in expanding the availability of KALBITOR® and delivering an acute HAE treatment to patients in need around the globe."
“Based on the clinical and commercial success of KALBITOR® as an acute treatment for HAE in the United States, we are excited to bring this important therapeutic to the Latin American market," commented David Muñoz Guzman, Chief Executive Officer of Pint. “We believe there is a great opportunity in Latin America to provide solutions for the management of HAE and we look forward to working with Dyax to bring KALBITOR to these markets."